Associations between urinary 6-sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes
- PMID: 33460308
- PMCID: PMC8015816
- DOI: 10.1111/jdi.13374
Associations between urinary 6-sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes
Abstract
Aims/introduction: There are limited reports on the association between melatonin levels and vascular complications in patients with type 2 diabetes. The aim of this study was to determine the association between urinary 6-sulfatoxymelatonin, which is a urinary metabolite of melatonin, and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes.
Materials and methods: This retrospective study included patients (167 patients with type 2 diabetes and 27 patients without diabetes adjusted for age and sex) admitted to the hospital who underwent measurement of urinary 6-sulfatoxymelatonin. The urinary 6-sulfatoxymelatonin/creatinine ratio (6-SMT) was calculated.
Results: The natural logarithmically scaled 6-SMT level (Ln 6-SMT) was significantly lower in type 2 diabetes patients (1.9 ± 1.1) compared with patients without diabetes (2.8 ± 1.0, P < 0.001). Multivariate linear regression analysis identified duration of diabetes, smoking status, urinary albumin-to-creatinine ratio, retinopathy and coronary heart disease as factors that could influence Ln 6-SMT levels in type 2 diabetes patients (R2 = 0.232, P < 0.001). Ln 6-SMT was associated with decreased odds of diabetic retinopathy, even after adjustment for various confounding factors (odds ratio 0.559, 95% confidence interval 0.369-0.846, P = 0.006). Similarly, Ln 6-SMT was associated with decreased odds of coronary heart disease (odds ratio 0.442, P = 0.030).
Conclusions: Our results showed the presence of low levels of Ln 6-SMT in type 2 diabetes patients relative to patients without diabetes. Furthermore, Ln 6-SMT is an independent risk factor of diabetic retinopathy and coronary heart diseases. These findings suggest that 6-SMT could be a useful biomarker for the prediction of micro- and macrovasculopathies in patients with type 2 diabetes.
Keywords: Diabetic vascular complications; Melatonin; Type 2 diabetes.
© 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Associations between nocturnal urinary 6-sulfatoxymelatonin, obstructive sleep apnea severity and glycemic control in type 2 diabetes.Chronobiol Int. 2017;34(3):382-392. doi: 10.1080/07420528.2016.1278382. Epub 2017 Jan 27. Chronobiol Int. 2017. PMID: 28128991
-
Urinary 6-sulfatoxymelatonin level in diabetic retinopathy patients with type 2 diabetes.Int J Clin Exp Pathol. 2014 Jun 15;7(7):4317-22. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25120815 Free PMC article.
-
Increased urinary albumin excretion is a marker of risk for retinopathy and coronary heart disease in patients with type 2 diabetes mellitus.Diabetes Res Clin Pract. 1998 Apr;40(1):45-51. doi: 10.1016/s0168-8227(98)00024-2. Diabetes Res Clin Pract. 1998. PMID: 9699090 Clinical Trial.
-
Urinary albumin excretion rate and cardiovascular disease in Spaniard type 2 diabetic patients.Diabetes Res Clin Pract. 1997 May;36(2):127-34. doi: 10.1016/s0168-8227(97)00043-0. Diabetes Res Clin Pract. 1997. PMID: 9229197
-
[Microalbuminuria as predictor of atherosclerotic cardiovascular disease in IDDM].Ugeskr Laeger. 1997 May 12;159(20):3010-4. Ugeskr Laeger. 1997. PMID: 9190730 Danish.
Cited by
-
Multidimensional sleep health and diabetic retinopathy: Systematic review and meta-analysis.Sleep Med Rev. 2024 Apr;74:101891. doi: 10.1016/j.smrv.2023.101891. Epub 2023 Dec 12. Sleep Med Rev. 2024. PMID: 38118339 Free PMC article.
-
Mechanism of action and experimental validation of key genes common to diabetic retinopathy and coronary heart disease based on multiple bioinformatics investigations.Front Genet. 2025 Mar 19;16:1548147. doi: 10.3389/fgene.2025.1548147. eCollection 2025. Front Genet. 2025. PMID: 40176795 Free PMC article.
-
Effects of Melatonin on Glycemic Variability in Type 2 Diabetes Mellitus: Protocol for a Crossover, Double-Blind, Placebo-Controlled Trial.JMIR Res Protoc. 2023 Aug 16;12:e47887. doi: 10.2196/47887. JMIR Res Protoc. 2023. PMID: 37410852 Free PMC article.
-
Association between anemia and dynapenia in older adults: a population-based study.Aging Clin Exp Res. 2022 Jun;34(6):1373-1379. doi: 10.1007/s40520-021-02064-x. Epub 2022 Jan 9. Aging Clin Exp Res. 2022. PMID: 35000139
-
Melatonin as a Chronobiotic and Cytoprotector in Non-communicable Diseases: More than an Antioxidant.Subcell Biochem. 2024;107:217-244. doi: 10.1007/978-3-031-66768-8_11. Subcell Biochem. 2024. PMID: 39693027 Review.
References
-
- Peschke E, Muhlbauer E. New evidence for a role of melatonin in glucose regulation. Best Pract Res Clin Endocrinol Metab 2010; 24: 829–841. - PubMed
-
- Waldhauser F, Dietzel M. Daily and annual rhythms in human melatonin secretion: role in puberty control. Ann N Y Acad Sci 1985; 453: 205–214. - PubMed
-
- Kozirog M, Poliwczak AR, Duchnowicz P, et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res 2011; 50: 261–266. - PubMed
-
- Favero G, Rodella LF, Reiter RJ, et al. Melatonin and its atheroprotective effects: a review. Mol Cell Endocrinol 2014; 382: 926–937. - PubMed
-
- Yang Y, Sun Y, Yi W, et al. A review of melatonin as a suitable antioxidant against myocardial ischemia‐reperfusion injury and clinical heart diseases. J Pineal Res 2014; 57: 357–366. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical